In re Cell Pathways, Inc., Securities Litigation II

203 F.R.D. 189, 2001 U.S. Dist. LEXIS 15875, 2001 WL 1173901
CourtDistrict Court, E.D. Pennsylvania
DecidedJuly 27, 2001
DocketNo. 01-CV-1189
StatusPublished
Cited by1 cases

This text of 203 F.R.D. 189 (In re Cell Pathways, Inc., Securities Litigation II) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Cell Pathways, Inc., Securities Litigation II, 203 F.R.D. 189, 2001 U.S. Dist. LEXIS 15875, 2001 WL 1173901 (E.D. Pa. 2001).

Opinion

MEMORANDUM AND ORDER

MCLAUGHLIN, District Judge.

These consolidated actions brought against Cell Pathways, Inc. (“Cell Pathways”), Robert Towarnicki, and Rifat Pamukcu seek damages for violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), and Rule 10b-5 promulgated thereunder. They are brought on behalf of purchasers of Cell Pathways securities between October 27, 1999 and September 22, 2000, and allege that the defendants made false and misleading statements concerning the drug Aptosyn.

The Court must now decide two competing motions for appointment as lead plaintiffs pursuant to Section 21D(a)(3)(B) of the Exchange Act, as amended by the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Plaintiffs Paul Didion, Sanford Goldfine, Michael Denton, Jr., and Richard Darlington (the “Didion plaintiffs”) have filed an amended motion for appointment as lead plaintiffs and for approval of their selection of the law firms of Berger & Montague, P.C. and Schiffrin & Barroway, LLP as co-lead counsel. Putative class members, Jonathan Arnold and Anita Garten, two economists, have filed a pro se motion to be selected as lead plaintiffs. Mr. Didion and Ms. Garten have not filed a complaint. The Court will grant the amended motion of the Didion plaintiffs for appointment as lead plaintiffs and will deny the motion of Mr. Arnold and Ms. Garten. The Court will also approve the Didion plaintiffs’ selection of co-lead counsel.

Under the PSLRA, the Court shall appoint as lead plaintiffis) the member or members of the class that the Court determines to be most capable of adequately representing the interests of the class. 15 U.S.C. § 78u-4(a)(3)(B). In determining who is the “most adequate plaintiff,” the Act provides that:

the court shall adopt a presumption that the most adequate plaintiff in any private action arising under this chapter is the person or group of persons that—
(aa) has either filed the complaint or made a motion in response to a notice under subparagraph (A)(i);
(bb) in the determination of the court, has the largest financial interest in the relief sought by the class; and
(cc) otherwise satisfies the requirements of Rule 23 of the Federal Rules of Civil Procedure.

15 U.S.C. § 78u-4(a)(3)(B)(iii)(I). Once the presumptively most adequate plaintiff is es[191]*191tablished, a member of the purported plaintiff class may rebut the presumption only upon proof that such plaintiff will not fairly and adequately protect the interests of the class or is subject to unique defenses that render such plaintiff incapable of adequately representing the class. 15 U.S.C. § 78u-4(a)(3)(B)(iii)(II).

The following three motions were initially filed with the Court: (1) pro se motion by Mr. Arnold and Ms. Garten for appointment as lead plaintiffs; (2) motion by Sanford D. Goldfine, Michael Denton, Jr., William Liss, Laura Liss, Jordan Liss, Jason Liss, and Salvatore Salibello for appointment as lead plaintiffs and for approval of Berman, DeValerio & Pease LLP and Schiffrin & Barroway as co-lead counsel; and (3) motion by Paul Didion, Richard Darlington, and Kendall Elsom for appointment as lead plaintiffs and for approval of Berger & Montague and Wolf Haldenstein Adler Freeman & Herz, LLP as co-lead counsel. The movants all filed timely motions as required by sub-paragraph (aa). Notice was published on March 22, 2001, and the initial motions were filed on May 21, 2001.

The latter two groups of movants ultimately combined to form a new group of movants (Paul Didion, Sanford Goldfine, Michael Den-ton, and Richard Darlington), represented by the law firms of Berger & Montague and Schiffrin & Barroway. On June 4, 2001, this new group, now known as the Didion plaintiffs, filed an amended motion for appointment of lead plaintiffs and approval of selection of co-lead counsel.1

The Court finds, and movants Arnold and Garten do not dispute, that the Didion plaintiffs have the largest financial interest in the relief sought by the putative class within the meaning of sub-paragraph (bb). The group as a whole claims losses of approximately $1,740,829; they individually claim approximate losses as follows: Paul Didion, $717,829; Sanford Goldfine, $432,000; Michael Denton, $360,000; and Richard Darlington, $231,000. Mr. Arnold and Ms. Gar-ten did not state their losses in their papers filed in support of their motion. At the hearing held on July 13, 2001, however, they conceded that individually, they do not have losses as great as Mr. Darlington, who has the smallest amount of losses in the Didion group. They even conceded that together they probably do not have losses as great as Mr. Darlington. July 13, 2001, Hearing, p. 11.

Rule 23, referred to in sub-paragraph (cc), requires that a proposed lead plaintiff demonstrate that he or she satisfies the typicality and adequacy requirements. See EZRA Charitable Trust v. Rent-Way, Inc., 136 F.Supp.2d 435, 444 (W.D.Pa.2001); In re Cephalon Securities Litig., No. CIV. A. 96-0633, 1998 WL 470160, *6 (E.D.Pa. Aug.12, 1998); Chill v. Green Tree Financial Corp., 181 F.R.D. 398, 407 n. 8 (D.Minn.1998); Gluck v. CellStar Corp., 976 F.Supp. 542, 546 (N.D.Tex.1997).

The typicality requirement of Rule 23 is satisfied where the representative’s claims arise from the same event, practice, or course of conduct that gives rise to the claims of the class members, and are based on the same legal theory. Hoxworth v. Blinder, Robinson & Co., Inc., 980 F.2d 912, 923 (3d Cir.1992); Krangel v. Golden Rule Resources, Ltd., 194 F.R.D. 501, 505 (E.D.Pa. 2000). The Didion plaintiffs satisfy this requirement, because, like all other class members, they: (1) purchased Cell Pathways securities during the Class Period; (2) at prices alleged to have been artificially inflated by alleged false and misleading statements made by the defendants and/or by the defendants’ failure to disclose material information; and (3) suffered damages as a result.

The adequacy requirement of Rule 23 turns on two factors: “(a) the plaintiffs attorney must be qualified, experienced, and generally able to conduct the proposed litigation, and (b) the plaintiff must not have interests antagonistic to those of the class.” Wetzel v. Liberty Mut. Ins. Co., 508 F.2d 239, 247 (3d Cir.), cert. denied, 421 U.S. 1011, 95 S.Ct. 2415, 44 L.Ed.2d 679 (1975). The inter[192]*192ests of the Didion plaintiffs appear well aligned with the interests of the putative class, and the Court has not been presented with any evidence of antagonism between the interests of the Didion group and the putative class. Further, the competency of counsel for the Didion plaintiffs is well established and is discussed below.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re Vicuron Pharmaceuticals, Inc. Securities Litigation
225 F.R.D. 508 (E.D. Pennsylvania, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
203 F.R.D. 189, 2001 U.S. Dist. LEXIS 15875, 2001 WL 1173901, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-cell-pathways-inc-securities-litigation-ii-paed-2001.